A sub-Saharan African country with both high tuberculosis (TB) incidence and human immunodeficiency virus (HIV) prevalence, Uganda is among the 20 countries with the highest TB-HIV burden worldwide. 1 TB incidence in Uganda in 2014-2015 was estimated to be 174 smear-positive cases per 100 000 population per year; 1 HIV prevalence in year olds was 7.4% in 2012-2013. 2 TB treatment success rates have greatly improved in Uganda, from 44% in 1995 to 75% in 2014, approaching the 2015 World Health Organization (WHO) target of 85%. 1 However, treatment success among TB patients living with HIV (PLHIV) are marginally lower than in their HIV-negative counterparts, both in Uganda (73% vs. 77%) 1 and globally (73% vs. 88% in 2014). 1 Low TB treatment success among PLHIV has been documented in various studies conducted in Africa. 3, 4 Rural health care settings report lower treatment success than national rates, [3] [4] [5] [6] although the introduction of the DOTS strategy may have improved rates. 7 A qualitative evaluation identified health system barriers to TB treatment outcomes such as stock-outs of drugs and laboratory supplies, low motivation and poor co-ordination of services, as well as contextual barriers such as the cost of seeking treatment. 8 Previous studies in Uganda showed that late presentation, patients lost to follow-up from treatment and inadequate treatment monitoring were associated with negative outcomes. 9, 10 In the present study, we aimed to use data from routinely collected government facilities to identify factors that limit treatment success in Ugandan urban and rural settings among the vulnerable population of PLHIV.
METHODS

Study design, setting and population
A retrospective cross-sectional study of Uganda National Tuberculosis and Leprosy Programme (NTLP) routine data was conducted in 26 government health facilities in Kampala and western Uganda. The Ugandan health system is structured into five health facility levels, ranging from village health team (HC-I) to specialised services at the national referral hospital. TB treatment and diagnosis is available from HC-III facilities upwards, and most TB-HIV integrated care is available from HC-IV facilities upwards. Facilities (HC-III and upwards) were randomly sampled from rural and urban sites supported by the Infectious Diseases Institute (IDI), Kampala, Uganda. Six of eight urban Kampala City Council Authority (KCCA) clinics were selected. Twenty rural facilities from Western Uganda were selected from 44 available (Appendix Tables A.1 and A.2). Eligible participants were new pulmonary TB cases, PLHIV, aged 14 years, who initiated anti-tuberculosis treatment in 2014. Participants were ineligible if they had multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB), or if their records were missing date of birth, age, TB diagnosis, TB regimen or date of treatment initiation. During the target period, the Uganda guidelines criteria for antiretroviral therapy (ART) were PLHIV with a CD4 count of <350 cells/μl regardless of WHO stage, or all PLHIV diagnosed with TB. 11, 12 A rural setting was defined as an area outside a city or big commercial town, while an urban setting was defined as a city or big commercial town.
Anti-tuberculosis treatment
All clinics enrolled in the study followed the Uganda NTLP guidelines 13 for TB diagnosis and treatment.
http://dx.doi.org/10.5588/pha. 16.0115 Setting: Government health centres and hospitals (six urban and 20 rural) providing tuberculosis (TB) treatment for people living with the human immunodeficiency virus (PLHIV) in central and western Uganda. Objective: To identify and quantify modifiable factors that limit TB treatment success among PLHIV in rural Uganda. Design: A retrospective cross-sectional review of routine Uganda National Tuberculosis and Leprosy Programme clinic registers and patient files of HIV-positive patients who received anti-tuberculosis treatment in 2014. Results: Of 191 rural patients, 66.7% achieved treatment success compared to 81.1% of 213 urban patients. Adjusted analysis revealed higher average treatment success in urban patients than in rural patients (OR 3.95, 95%CI 2.70-5.78, P < 0.01, generalised estimating equation model). Loss to follow-up was higher and follow-up sputum smear results were less frequently recorded in TB clinic registers among rural patients. Patients receiving treatment at higher-level facilities in rural settings had greater odds of treatment success, while patients receiving treatment at facilities where drug stock-outs had occurred had lower odds of treatment success. Conclusion: Lower reported treatment success in rural settings is mainly attributed to clinic-centred factors such as treatment monitoring procedures. We recommend strengthening treatment monitoring and delivery.
Public Health Action
New pulmonary TB patients were given first-line anti-tuberculosis treatment comprising a 2-month intensive phase of rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) (2RHZE) and either a 6-month continuation phase comprising ethambutol (E) and isoniazid (H) (as combination: 6EH), or 4 months of rifampicin (R) and isoniazid (H) (4RH). The 4RH regimen was standard care for people aged 15 years, and was used during drug stock-outs in some clinics.
Participants and data collection
Records were extracted between December 2015 and January 2016. To attain a targeted sample size of 396 cases (198 cases each from rural and urban areas), we required at least 33 cases per clinic. To allow for missing data, we targeted 40 cases and therefore included all eligible cases in facilities with 40 cases, while in those with >40 cases, systematic sampling with probability proportional to size was used.
Participants' TB and HIV data were obtained from registers, HIV care cards in patient files and ART registers. Patients' HIV care identification clinic numbers (IDCNO) were used to match TB and HIV data, but when these were missing from TB registers, demographic characteristics were used for matching. If a patient's file could not be traced, the next eligible patient in the register was considered. Clinic-level data on drug stockouts, staffing, geographic location, possession of microscopy and other clinic activities such as patient tracing were obtained from review of annual reports and from staff at the TB clinic.
Data were double-entered into Epi Info™ 7 statistical software (Centers for Disease Control and Prevention, Atlanta, GA, USA), verified for consistency, and transferred to Stata 13.1 software (Stata LP, College Station, TX, USA) for analysis.
Statistical analysis and outcomes
With 80% power, a significance of 5% and a sampling ratio of 1:1 in urban:rural clinics, 322 patients were required to detect a difference in treatment success, from 71% 14 in urban clinics to 56% in rural clinics, based on an estimated difference of 15% between success rates. To allow for clustering effects, the sample size was inflated by 20%, making a target sample size of 396.
The primary outcome was the proportion of participants with treatment success (defined as cure or treatment completed) comparing rural and urban participants. Secondary outcomes were standard end of treatment measures, defined according to the Uganda NTLP and the WHO 1,13 (Appendix Table A .3). Logistic generalised estimating equations (GEE) models with clinics as clusters, odds ratios (ORs) and 95% confidence intervals (CIs) were used to examine measured potential predictors of TB treatment success. Factors examined in the analysis included patient characteristics at TB treatment start (age, sex, CD4 cell count, body mass index [BMI], ART treatment history, living in a different subcounty from the clinic, and nature of TB diagnosis: bacteriologically confirmed or clinically diagnosed), status during TB treatment (timing of ART initiation among the ART-naïve, comorbidities that interfere with patient adherence, such as stomach ulcer and malaria, missed TB doses, missed clinic appointments, received 4 weeks' supply of anti-tuberculosis drugs for the intensive phase) and clinic factors (health facility level, TB drug stock-outs, number of staff at TB clinic by qualification, patient load at TB clinic). All analyses used inverse probability weighting to account for unequal sampling probability of participants at each clinic. Sex, age and being on ART at the start of anti-tuberculosis treatment were a priori factors included in the adjusted model. All variables with P values <0.3 were then added to the adjusted model and removed if P > 0.3 in the adjusted model. All remaining variables were tested again one by one, and included if P < 0.3 in the adjusted model.
Ethical considerations
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RESULTS
Of 2810 individuals initiated on anti-tuberculosis treatment during the study period in 26 clinics studied, 871 met the inclusion criteria: TB and HIV data were obtained for 191 rural and 213 urban participants ( Figure 1 ). The majority were male (61.1%), and had been prescribed 2RHZE/6EH (92.0%); the mean age was 35 years (standard deviation 10) and 40.7% were on ART at the start of anti-tuberculosis treatment ( Table 1) . At 2 months, 235 (51.2%) participants had follow-up sputum smear results, 183 (42.4%) at 5 months and 174 (40.9%) at 8 months ( Figure 2 ). Treatment was successful for 81.1% of 213 participants in urban facilities and 66.7% of 191 participants in rural facilities ( Table 2) . Urban patients were more likely to have achieved treatment success than rural patients (adjusted OR [aOR] 3.95, 95%CI 2.70-5.78, P < 0.01; Table 3 ). There was no evidence of an independent Public Health Action association of sex, age and ART status with treatment success (Table 3). Analysis of secondary outcomes revealed that 41.4% were cured (17.0% in rural, 65.7% in urban areas), 32.5% completed treatment (49.7% in rural, 15.4% in urban areas), 1% had failed and 8.1% had died, whereas 6.9% of patient outcomes could not be evaluated and 10.1% of the participants had become lost to follow-up (LTFU), with rural clinics having a higher proportion of cases LTFU than urban clinics (16.6% vs. 3.5%; Table 2 ).
The median number of participants per clinic was nine (interquartile range [IQR] 4-13) in rural and 34 (IQR 32-39) in urban , urban (n = 171, 80%), rural (n = 125, 65%); for BMI: overall (n = 289, 72%), urban (n = 152, 71%), rural (n = 137, 72%); lived in different subcounty to clinic: overall (n = 7, 2%), urban (n = 0, 0%), rural (n = 7, 4%); prescribed 8 weeks' supply during the continuation phase: overall (n = 55, 14%), urban, (n = 18, 8%), rural (n = 37, 19%). Public Health Action facilities. Sputum smear results in TB registers were significantly more likely to be recorded in urban than in rural facilities at all times (P < 0.001), and did not depend on the level of health facility (P = 0.480). Clinic-level treatment success ranged from 72% to 91% in urban and 0% to 100% in rural facilities. The two clinics with 0% success had less than five patients; one had no counsellor and one reported TB drug stock-outs during the period studied. Having a TB drug stock-out was associated with lower treatment success (aOR 0.38, 95%CI 0.24-0.60, P < 0.01), while having a counsellor in the clinic was associated with on average 55% higher odds of treatment success (aOR 1.55, 95%CI 1.05-2.28, P = 0.03; Table 3 ). Treatment success increased with health facility level in rural areas: 49.1% at HC-III, 64.8% at HC-IV and 76.4% at hospital level (P value for interaction <0.01: Appendix Table A.4) . For urban clinics, treatment success was highest in hospitals (90.9%) and lowest in HC-IV facilities (72.4%). TB-HIV integrated services were being implemented in five of the six urban health facilities and nine of the 20 rural health facilities during the study period.
DISCUSSION
TB treatment success rates among PLHIV vary widely among sub-Saharan African countries, [15] [16] [17] [18] [19] [20] [21] and our study findings fit within this range. Studies that reported better treatment success rates than our study had more well-organised community-based DOTS programmes and better patient tracing 7, 17, [22] [23] [24] than most rural clinics in our study. The higher proportion of patients reported as LTFU by rural clinics was likely related to patient characteristics: such patients lived further from health facilities, presented later for treatment, were more likely to be malnourished, and had lower CD4 cell counts at diagnosis than their urban counterparts and received less treatment monitoring than urban patients, consistent with other studies in Uganda and elsewhere in sub-Saharan Africa. 3, 5, 8, 21, 25 Treatment monitoring was key to the improved treatment success in urban clinics. The availability of follow-up sputum smear results was less common for rural patients, despite the presence of microscopes in all facilities. Facilities reported lack of laboratory supplies such as reagents, which limited the performance of sputum testing. In addition, data management was poor in most rural clinics, resulting in missing sputum results and treatment outcomes in TB registers even when the tests were performed. Efforts were made to obtain missing outcome data, but we were limited by what was recorded in the TB registers. A comparable rural Ugandan study found that of 264 511 patient encounters, 1.8% had sputum smear microscopy prescribed, of which 60% underwent a complete evaluation. 26 Fewer rural health facilities had TB-HIV integrated care than urban facilities. Rural clinics may have tailored TB appointments to coincide with HIV clinic appointments for HIV patients on anti-tuberculosis treatment, specifically due to the longer distances to the health facility. This could have contributed to poor adherence to anti-tuberculosis treatment among rural patients due to a lack of adequate monitoring.
Stock-outs in the facilities studied were most common for the drug combination administered during the intensive phase (RHZE), and lasted on average for 2 months (maximum 8 months). As in other studies, 27 causes of reported stock-outs were delayed supply of drugs from national medical stores and poor forecast of requirements of drugs by the clinics. Solutions reported were borrowing from nearby clinics or issuing alternative drugs. Drug stock-outs of antiretroviral or anti-tuberculosis drugs were also reported in 25% of 2454 South African health facilities studied in 2014. 27 Adequate funding and commitment among the stakeholders responsible for procurement, custody and issuing of drugs may reduce stock-outs of essential drugs in public health facilities in sub-Saharan Africa. 27 Furthermore, the presence of counsellors in the team of TB clinic staff is undoubtedly related to better-resourced-and proba- 
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bly higher level-clinics. Counselling services have been previously shown to improve treatment success. 9 The higher treatment success rates in urban sites may be attributable to programmes being implemented in KCCA clinics (TB Care 1 28 and TRACK-TB [project ongoing until 2017]), but not in rural clinics. These programmes aimed to improve the quality of TB treatment care, adherence, treatment outcomes, data quality/documentation and drug management. The reports from such programmes have shown significant improvements in documentation in patients' medical records as a result of TB staff training and support supervision. 28 Such programmes should be extended to rural settings to achieve nationwide improvements in treatment success. The interrelationship between patient-level and clinic-level factors highlights the obstacles to improving treatment success. 29, 30 Both a strength and a weakness of this study was that it used data routinely collected from public health facilities at primary health care level. The inclusion of public health facilities from outlying rural areas provided good representation of routine TB care in Uganda, although routine hospital data may suffer from incomplete recording, resulting in missing data, including outcome data. We correctly analysed the data using sampling weights to account for multiple site sampling. Because we restricted data collection to clinics supported by IDI and to patients with linked TB-HIV data, this may have limited the generalisability of our findings to clinics that were not providing these services. This may have led to an estimation of greater treatment success than would be expected in non-IDI clinics. However, this should not affect the urban-rural comparison, as this restriction was imposed in both areas. Furthermore, many proxy variables had to be used, for example distance to clinic (not collected in data sources used), which was approximated by residence in another subcounty. Linkage of TB and HIV health records was less likely in rural settings, among males and among LTFU patients, which may have overestimated treatment success due to the exclusion of high numbers of LTFU patients that would otherwise be categorised as unfavourable outcomes.
CONCLUSION
The lower reported treatment success rates in rural clinics are likely a combination of patient-centred factors, such as late presentation and distance to clinic, and clinic-centred factors, such as staff unavailability for treatment monitoring and follow-up. We recommend the reinforcement of community-based TB treatment, especially in rural settings, active tracing of patients who miss appointments and increased staff training on treatment monitoring and delivery, and good data management. 
Term Definition
Bacteriologically confirmed TB case Defined as a patient with a biological specimen that is positive on smear microscopy, culture or WRD, such as Xpert ® MTB/RIF Clinically diagnosed TB case Patient who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with active TB by a clinician or any other medical practitioner who has prescribed the patient a full course of antituberculosis treatment. This also includes X-ray abnormalities or suggestive histology and EPTB cases without laboratory confirmation PTB Refers to any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree. This also includes miliary TB. Patients with both PTB and EPTB are classified as PTB EPTB Refers to any bacteriologically confirmed or clinically diagnosed TB case involving organs other than the lungs, such as pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges TB relapse Patient who has previously been treated for TB, was declared cured or treatment completed at the end of their most recent course of treatment, and is now diagnosed with a recurrent episode of TB (either a true relapse or a new episode of TB caused by re-infection) Treatment after failure Patient who was previously treated for TB and whose treatment failed at the end of their most recent course of treatment HIV-positive TB patient Refers to a bacteriologically confirmed or clinically diagnosed TB case who is HIV-positive at the time of TB diagnosis or any other evidence of enrolment into HIV care, such as enrolment into pre-ART register or in ART register once ART has been started Cure A PTB patient with bacteriologically confirmed TB at the beginning of treatment, who is smear-or culturenegative in the last month of treatment and on at least one previous occasion Treatment completed A TB patient who completed treatment without evidence of failure BUT with no record to show that sputum smear or culture results in the last month of treatment and on at least one previous occasion were negative, either because tests were not performed or results were unavailable Treatment failed A patient whose sputum smear or culture is positive at month 5 or later during treatment Died A TB patient who dies for any reason before starting or during treatment Lost to follow-up A patient who did not start treatment or whose treatment was interrupted for 2 consecutive months Not evaluated A TB patient for whom no treatment outcome is assigned. This includes cases transferred out to other treatment units as well as TB patients whose treatment outcome is unknown to the reporting unit 
Public Health Action
Public Health Action (PHA) The voice for operational research. Marco de referencia: El estudio se llevó a cabo en centros de salud y hospitales del sector público, seis en entornos urbanos y 20 en medio rural y consistió en suministrar el tratamiento antituberculoso a las personas positivas frente al virus de la inmunodeficiencia humana (VIH) en la región central y occidental de Uganda. Objetivo: Determinar y cuantificar los factores modificables que limitan la eficacia del tratamiento antituberculoso en las personas positivas frente al VIH en las zonas rurales de Uganda. Método: Fue este un estudio transversal retrospectivo de análisis de los registros corrientes y las historias clínicas de los pacientes positivos frente al VIH, en los consultorios del Programa Nacional contra la Tuberculosis y la Lepra de Uganda en el 2014. Resultados: De los 191 pacientes de entornos rurales, el 66,7% logró un tratamiento eficaz y en los 213 pacientes en medio urbano esta proporción fue 81,1%. Un análisis ajustado reveló un promedio de éxito terapéutico más alto en los pacientes urbanos en comparación con los pacientes rurales (OR 3,95; IC95% de 2,70 a 5,78; P < 0,01, según un modelo de ecuaciones de estimación generalizadas). En medio rural, se observó una mayor pérdida durante el seguimiento y se consignaban con menor frecuencia los resultados de las baciloscopias de seguimiento en los registros de tuberculosis de los consultorios. Los pacientes que recibían tratamiento en los establecimientos de nivel de atención más alto en medio rural tenían mayores posibilidades de éxito terapéutico. Los pacientes que recibían tratamiento en centros que presentaban desabastecimientos de medicamentos tuvieron menos probabilidades de lograr un tratamiento eficaz. Conclusión: La menor proporción de éxito terapéutico notificada en los entornos rurales se debe en su mayor parte a factores que dependen del consultorio, como los procedimientos de supervisión del tratamiento. Se recomienda reforzar la supervisión y el suministro del tratamiento antituberculoso.
